Skip to main content
. 2024 Jun 28;119(12):2398–2407. doi: 10.14309/ajg.0000000000002924

Figure 2.

Figure 2.

Change from baseline in overall EoE-SQ Severity score at weeks 12 and 24 (a) and individual severity items of the EoE-SQ at week 24 (b). *Nominal P ≤ 0.05, **nominal P ≤ 0.01 dupilumab vs placebo. EoE-SQ, eosinophilic esophagitis Symptom Questionnaire; LS, least squares; qw, once weekly.